Drugs / mRNA-1645-CoreG28v2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06694753 | Dec 2025 → Dec 2026 expected | HIV infectious disease | International AIDS Vaccine Initiative | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1645-CoreG28v2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694753 ↗ |
| Modality | Messenger RNA (mRNA) | “Core-g28v2 60mer will be delivered using an mRNA-LNP platform.” NCT06694753 ↗ |
| Route | Intramuscular | “To be administered by IM injection at doses of 10 or 30 mcg.” NCT06694753 ↗ |